Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis” by Sparks et al

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

(2021) Jeffrey A Sparks et al.   ANNALS OF THE RHEUMATIC DISEASES

Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry” by Sparks et al

(2021) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

(2021) Michael Dougan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

(2021) Patrícia O. Guimarães et al.   NEW ENGLAND JOURNAL OF MEDICINE

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

(2020) Andre C. Kalil et al.   NEW ENGLAND JOURNAL OF MEDICINE

American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 3

(2020) Ted R. Mikuls et al.   Arthritis & Rheumatology